First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Inclusion Criteria: * Histologically confirmed: * Follicular lymphoma grade 1, 2, 3a * Marginal zone lymphoma, including MALT type * Small lymphocytic lymphoma (BM inv. \< 30%) * Lymphoplasmacytic lymphoma * Clinical stage II-IV (Ann Arbor). Stage I is allowed if bulky (Ø \> 7 cm) or if radiotherapy is not appropriate in judgment of treating physician * Measurable lesion(s) in at least one site * Patients previously untreated * Patients presenting with symptoms requiring treatment: * Progressive disease * Symptoms related to tumor bulk * Cytopenias related to bone marrow and/or spleen involvement B symptoms * Age ≥ 18 years * Performance status \</=2 * Written informed consent Exclusion Criteria: * Grade 3b FL * Transformed lymphoma * CNS involvement * Patient taking steroids for \> 2 weeks during last 4 weeks at a dose equivalent to ≥ 20 mg prednisone * Other malignancy * Major surgery within 4 weeks * Hb \< 8 g/dl, ANC \< 1.5 x 109/L, Plt \<100 109/L unless due to lymphoma * Impairment of renal function (creatinine \> 1.5 x UNV) or liver function (total bilirubin 1.5 x UNV, SGOT \> 2.5 x UNV not due to lymphoma * Known infection, with HBV, HCV (acute \< 6 mos. or chronic hepatitis) or HIV * Serious underlying medical conditions * Life expectancy \< 6 months * Known allergy to murine protein